权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Liver lobule zonation, hepatocellular carcinoma (HCC) and β-catenin mediated hepatitis B virus (HBV) biosynthesis

肝小叶分区、肝细胞癌 (HCC) 和 β-连环蛋白介导的乙型肝炎病毒 (HBV) 生物合成

基本信息

批准号：
10059188
负责人：
Alan McLachlan
金额：
$ 36.58万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10059188
关键词：
APC gene Acute Address Anabolism Animal Model Anthelmintics Antiviral Agents Antiviral Therapy Biological Models Capsid Cell Culture Techniques Cell Line Cells Cessation of life Chronic Chronic Hepatitis B DNA Methylation DNA-Directed DNA Polymerase Data Development Drug resistance Epigenetic Process Evaluation FDA approved Gene Targeting Genes Genetic Transcription Goals Grant Health HepG2 Hepatitis B Virus Hepatocyte Human Lead Liver Liver Cirrhosis Liver neoplasms Lobule Malignant neoplasm of liver Mediating Mediator of activation protein Metabolism Modality Molecular Mus PI3K/AKT PTEN gene Pathway interactions Pharmaceutical Preparations Phenotype Play Primary carcinoma of the liver cells RNA RNA-Directed DNA Polymerase Regulation Resolution Reverse Transcriptase Inhibitors Reverse Transcription Role Signal Transduction Signal Transduction Pathway Small Interfering RNA Tamoxifen Tissues Transcription Coactivator Transgenic Mice Variant Viral Viral Genome Viral Load result Virus Diseases Virus Replication base beta catenin chronic liver disease curative treatments drug development gene product hepatoma cell histone modification human pathogen in vivo inhibitor/antagonist interest knock-down man mouse model mutant novel polypeptide targeted cancer therapy targeted treatment therapeutic target transcription factor tumor tumor initiation

项目摘要

Project Summary and Relevance. Hepatitis B virus (HBV) infection is a worldwide health problem. It is estimated that there are 200 to 500 million HBV chronic carriers in the world for whom, to date, there is no reliable treatment. HBV causes both acute and chronic liver disease and is responsible for an estimated one million deaths annually from liver cirrhosis and primary hepatocellular carcinoma (HCC). Currently available therapies reduce viral loads but fail to resolve chronic HBV infections and hence require lifelong treatment. A major obstacle to the resolution of chronic HBV infections is the limited number of HBV targets that are suitable for the development of antiviral therapies. All the current antiviral therapies target the HBV reverse transcriptase/DNA polymerase, often leading to the development of drug-resistant variants. Curative therapies will require the identification of additional antiviral targets. Cellular gene products that make a significant contribution to HBV biosynthesis represent potential additional antiviral targets which alone or in combination with current HBV reverse transcriptase inhibitors may represent a potential curative therapy. One potential cellular gene target that might represent an HBV antiviral target is β-catenin, the terminal mediator of the Wnt/β-catenin signal transduction pathway which can be inhibited by the FDA-approved drug, Pyrvinium. Preliminary data indicate that β-catenin can activated HBV transcription and replication in cell culture and β-catenin activity correlates with viral biosynthesis in vivo in the HBV transgenic mouse model of chronic viral infection. Consequently, cell culture analysis will be performed to define the molecular mechanisms mediating β-catenin enhanced HBV transcription and replication. Characterization of inducible liver-specific β-catenin-null and APC-null (β-catenin activated) HBV transgenic mice will indicate the in vivo contribution of β-catenin to the restricted localization of viral biosynthesis to pericentral hepatocytes within the liver lobule and restricted viral expression within HCC tissue. Furthermore, treatment of HBV replicating cells and transgenic mice with Pyrvinium will indicate if an available FDA approved drug can modulate the Wnt/β-catenin signal transduction pathway and act as an antiviral therapy. Defining the role of the Wnt/β-catenin signal transduction pathway in determining the level of HBV biosynthesis may lead to the identification of cellular therapeutic targets that are amenable to the further development of novel modalities to resolve rather than simply treat chronic HBV infection.

项目总结和相关性。